GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Earnings Yield (Joel Greenblatt) %

Roivant Sciences (Roivant Sciences) Earnings Yield (Joel Greenblatt) % : 128.21% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Earnings Yield (Joel Greenblatt) %?

Roivant Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $3,369.5 Mil. Roivant Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $4,301.8 Mil. Roivant Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 128.21%.

The historical rank and industry rank for Roivant Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ROIV' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -114.09   Med: -24.01   Max: 166.67
Current: 163.93

During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of Roivant Sciences was 166.67%. The lowest was -114.09%. And the median was -24.01%.

ROIV's Earnings Yield (Joel Greenblatt) % is ranked better than
99.71% of 1394 companies
in the Biotechnology industry
Industry Median: -15.435 vs ROIV: 163.93

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Roivant Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Roivant Sciences Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Roivant Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Earnings Yield (Joel Greenblatt) % Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23
Earnings Yield (Joel Greenblatt) %
- -44.44 -24.63

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.19 -24.63 -16.18 -13.37 128.21

Competitive Comparison of Roivant Sciences's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Roivant Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Earnings Yield (Joel Greenblatt) % falls into.



Roivant Sciences Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Roivant Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-1196.866/4864.26734
=-24.61 %

Roivant Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,301.8 Mil.



Roivant Sciences  (NAS:ROIV) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Roivant Sciences Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences (Roivant Sciences) Business Description

Industry
Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Executives
Eric Venker officer: President & COO C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester director C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold director 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp 10 percent owner, other: Director by Deputization 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar officer: Chief Accounting Officer C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p. 10 percent owner AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik officer: CFO SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy director C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000

Roivant Sciences (Roivant Sciences) Headlines

From GuruFocus

QVT Financial LP Reduces Stake in Roivant Sciences Ltd

By GuruFocus Research 10-03-2023

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

By Stock market mentor Stock market mentor 02-03-2023